KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Assets: 2009-2024

Historic Assets for Teva Pharmaceutical Industries (TEVA) over the last 16 years, with Dec 2024 value amounting to $39.3 billion.

  • Teva Pharmaceutical Industries' Assets fell 4.55% to $39.9 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $39.9 billion, marking a year-over-year decrease of 4.55%. This contributed to the annual value of $39.3 billion for FY2024, which is 9.55% down from last year.
  • Latest data reveals that Teva Pharmaceutical Industries reported Assets of $39.3 billion as of FY2024, which was down 9.55% from $43.5 billion recorded in FY2023.
  • Teva Pharmaceutical Industries' Assets' 5-year high stood at $50.6 billion during FY2020, with a 5-year trough of $39.3 billion in FY2024.
  • Over the past 3 years, Teva Pharmaceutical Industries' median Assets value was $43.5 billion (recorded in 2023), while the average stood at $42.3 billion.
  • Its Assets has fluctuated over the past 5 years, first fell by 11.88% in 2020, then rose by 1.21% in 2023.
  • Over the past 5 years, Teva Pharmaceutical Industries' Assets (MRY) stood at $50.6 billion in 2020, then dropped by 5.87% to $47.7 billion in 2021, then dropped by 7.67% to $44.0 billion in 2022, then decreased by 1.21% to $43.5 billion in 2023, then decreased by 9.55% to $39.3 billion in 2024.
  • Its last three reported values are $39.3 billion in FY2024, $43.5 billion for FY2023, and $44.0 billion during FY2022.